PinnyPeptide

Bronchogen vs Cartalax

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Bronchogen

Bioregulators

Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue.

Peptide B

Cartalax

Bioregulators

Khavinson short peptide bioregulator targeting chondrocytes and connective tissue.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists longer via gene-expression modulation

FDA status

Not FDA approved.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Bronchogen effects

  • Reported restoration of bronchial epithelial function
  • Improvement in pulmonary function tests (Russian observational data)
  • Reduction in COPD/bronchitis exacerbation frequency
  • Improved dyspnea and exercise tolerance
  • Anti-inflammatory effects in bronchial tissue

Cartalax effects

  • Reported support of chondrocyte function and cartilage matrix synthesis
  • Improvements in joint pain and mobility (Russian observational)
  • Possible slowing of age-related cartilage degradation
  • Recovery support after cartilage injury
  • Modulation of connective-tissue gene expression

Bronchogen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Occasional allergic reactions (rare)
  • Limited Western safety validation

Cartalax side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation

Bronchogen dosing ranges

Bronchial function support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Cartalax dosing ranges

Joint / cartilage support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full Bronchogen guide → Full Cartalax guide →

Bronchogen vs Cartalax — common questions

What is the difference between Bronchogen and Cartalax?

Bronchogen: Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue. Typical dose 1,000-5,000 mcg. Cartalax: Khavinson short peptide bioregulator targeting chondrocytes and connective tissue. Typical dose 1,000-5,000 mcg. Both fall under the Bioregulators category.

Can you stack Bronchogen and Cartalax?

Stacking Bronchogen with Cartalax is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Bronchogen or Cartalax?

Bronchogen is typically dosed: Once daily (SubQ) or sublingual for Bronchial function support. Cartalax is typically dosed: Once daily (SubQ) or sublingual for Joint / cartilage support.

Are Bronchogen and Cartalax FDA approved?

Bronchogen: Not FDA approved. Cartalax: Not FDA approved.

Related peptide comparisons

bronchogen vs cardiogenbronchogen vs cortagenbronchogen vs crystagenbronchogen vs ovagenbronchogen vs pancragencardiogen vs cartalax

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free